Skye Bioscience Inc. (SKYE), a clinical-stage biotechnology company developing new treatments that help reduce excess body fat and improve metabolic health, has a clinical trial catalyst to watch in the near term.
The company's lead drug candidate is Nimacimab, a peripherally acting antibody targeting the cannabinoid 1 receptor ("CB1"), which has been implicated as an important target in cardiometabolic diseases, including obesity and renal complications.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com